An investigation into drug products withdrawn from the EU market between 2002 and 2011 for safety reasons and the evidence used to support the decision-making
Open Access
Abstract
Objectives The objective of this study was to determine the nature of evidence used to support the withdrawal of marketing authorisations of drug products for safety reasons throughout the European Union (EU) between 2002 and 2011. Setting Products withdrawn, either by a medicines agency or a marketing authorisation holder, during the period 2002–2011 were identified by conducting detailed searches of the WHO, the European Medicines Agency (EMA) and national medicines agency websites throughout the EU plus Norway, Iceland and Liechtenstein. The scientific evidence used to support the decision was identified from a search within PubMed, the EMA and national medicines agencies websites. Information about spontaneous case reports entered into EudraVigilance and unavailable on the EMA website was received by email from the EMA. Results 19 drugs were withdrawn from the market, throughout the EU, for safety reasons from 2002 to 2011. Case reports were cited in 95% of withdrawals (18/19) and case–control studies (4/19), cohort studies (4/19), randomised controlled trials (RCTs) (12/19) or meta-analysis (5/19) were cited in 63% of withdrawals (12/19). Cardiovascular events or disorders were the main reason for withdrawal (9/19), followed by hepatic disorders (4/19) and neurological or psychiatric disorders (4/19). Conclusions This study has shown that the level of evidence used to support drug withdrawal has improved during the past 10 years, with an increased use of case–control studies, cohort studies, RCTs and meta-analyses. This research has demonstrated that such studies have contributed to decision-making in almost two-thirds of cases.Keywords
This publication has 6 references indexed in Scilit:
- Is spontaneous reporting always the most important information supporting drug withdrawals for pharmacovigilance reasons in France?Pharmacoepidemiology and Drug Safety, 2012
- Safety assessment of new antithrombotic agents: Lessons from the EXTEND study on ximelagatranThrombosis Research, 2009
- The nature of the scientific evidence leading to drug withdrawals for pharmacovigilance reasons in FrancePharmacoepidemiology and Drug Safety, 2006
- An Assessment of the Publicly Disseminated Evidence of Safety Used in Decisions to Withdraw Medicinal Products from the UK and US MarketsDrug Safety, 2006
- The use of evidence in pharmacovigilanceEuropean Journal of Clinical Pharmacology, 2001
- Methodological and political issues in clinical pharmacology research by the year 2000.European Journal of Clinical Pharmacology, 2000